"...I look forward to the next chapter in driving ERT’s leadership role in bringing better clinical products to market,” commented Jim Corrigan.
PHILADELPHIA (PRWEB) September 10, 2014
ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, today announced that Jim Corrigan, who has served as Executive Vice President and Chief Operating Officer since August 2013, will assume the role as its new President and Chief Executive Officer, as well as a member of the board, effective immediately. Its former President and Chief Executive Officer, Jeffrey S. Litwin, M.D. will be assuming a new role as Chief Scientific and Strategic Consultant. Jeff began his career with ERT fourteen years ago and has capably led the organization as CEO for the past three years. In this new role, Jeff will be able to provide substantial support to the product and business development organizations where his consulting expertise and deep knowledge of the clinical trials space will be well utilized.
“I have great respect for Jeff and I am excited that we will continue to have the opportunity to leverage the expertise and insight that he brings,” commented Mr. Corrigan. “I am so honored to have been asked to be the next CEO with the ability to build upon ERT’s great foundation and brand recognition of Getting it Done. Right.”
Jim’s knowledge of the life sciences and healthcare industry stems from his 25 years of experience in executive leadership roles at General Electric (GE) leading global teams in imaging equipment/services, healthcare IT, and minimally invasive surgery to significant growth. Over the last year, Jim has been responsible for overseeing, developing, and setting the strategic direction for ERT
“My tenacious commitment to our clients and employees, to innovation and quality, and to providing strong results from which to grow our organization remains unchanged” said Mr. Corrigan. “Since joining ERT, our leadership team set a go-forward strategy that has been successfully tested and our investments in quality and innovation are at an all-time high. I look forward to the next chapter in driving ERT’s leadership role in bringing better clinical products to market.”
ERT (http://www.ert.com) is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services, and consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process throughout the product lifecycle. ERT delivers the most widely deployed solutions in centralized cardiac safety, respiratory services, suicide risk assessment and Clinical Outcome Assessments (COAs) – which includes patient, clinician, and observer reported outcomes. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes, and delivers safety and efficacy data critical to the approval, labeling, and reimbursement of pharmaceutical products. ERT is a global organization with headquarters in Philadelphia, PA and offices throughout the U.S., U.K., Japan, and Germany.